NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)
Neurim Pharmaceuticals (“Neurim”) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…